2 assets in Seminal Vesicle Adenocarcinoma

Therapeutic assets addressing Seminal Vesicle Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Seminal Vesicle Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Seminal Vesicle Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)